Concept Life Sciences Makes Scientific and Commercial Leadership Appointments
Concept Life Sciences (Concept), the integrated drug discovery, development and analytical services company, today announced it has appointed Dr Michael Donaldson as Principal Scientist in its Dermal department, and Dr Tim Calvert as Vice President of Business Development, Integrated Discovery Services, Europe.
Tim has extensive experience in the delivery of integrated drug discovery and development solutions, supporting organisations ranging from virtual companies to global pharma. Tim joins Concept from Aptuit where he held various roles, most recently Senior Director of Integrated Drug Development, during which time he was responsible for executing complex and accelerated drug development programmes. Prior to joining Aptuit, he was at Lonza, where he led and secured Israel’s first gene therapy development programme, Catalent Pharma Solutions, and Invitrogen.
Michael has over 17 years’ experience in the pharmaceutical development and manufacturing industry. Most recently he was Director of Biology in Dermatology Therapy Area at GlaxoSmithKline. Previous experience includes formulation and manufacturing at Stiefel, a GSK company, development of skin permeation products at MedPharm, and developing liquid chromatography methods for antibiotic production analysis within the QC/QA group at Roche Pharmaceuticals. In his new role at Concept, Michael will be responsible for Dermal Services.
Philip Payne, Chief Commercial Officer, Concept Life Sciences, said: “We are delighted to welcome Michael and Tim to Concept. Their notable scientific and commercial backgrounds will be invaluable in supporting the continued expansion of the group.”
Diamonds Could Decrease Cost of Imaging and Spectroscopy DevicesNews
A new approach shows great promise for enhancing the signal from magnetic resonance imaging (MRI) and nuclear magnetic resonance (NMR) using lasers without expensive magnets.
Antitumor Immune Function in Liver Controlled by Gut MicrobiomeNews
Scientists have found a connection between bacteria in the gut and antitumor immune responses in the liver. The study showed that bacteria found in the gut of mice affect the liver’s antitumor immune function. The findings have implications for understanding the mechanisms that lead to liver cancer and for therapeutic approaches to treat them.READ MORE
Comments | 0 ADD COMMENT
2nd Annual Artificial Intelligence in Drug Development Congress
Sep 20 - Sep 21, 2018